Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies

Costas Lallas, MD
Published: Tuesday, Aug 29, 2017



Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Checkpoint inhibitors are generating more interest, states Lallas. As far as the T-cell response goes, there are agents which can move the immune process ahead. There are stimulating agents, which are being looked at actively in clinical trials.

Checkpoint inhibitors allow T cells to be activated, as well as the cellular response against those malignancies, which is why they have shown efficacy, explains Lallas.
 
SELECTED
LANGUAGE


Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Checkpoint inhibitors are generating more interest, states Lallas. As far as the T-cell response goes, there are agents which can move the immune process ahead. There are stimulating agents, which are being looked at actively in clinical trials.

Checkpoint inhibitors allow T cells to be activated, as well as the cellular response against those malignancies, which is why they have shown efficacy, explains Lallas.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x